Abstract
Cytokines are intercellular messengers that have an important role in the development and maintenance of cutaneous inflammation. The primacy of cytokines in eliciting cutaneous immune responses makes them a highly attractive target for new biological response modifiers. Targeting of cytokines is still in its infancy for therapy of skin disease. However, blocking tumour necrosis factor α by infliximab or etanercept has shown particular promise, especially in the management of psoriasis. Anecdotally, this approach is also effective for a variety of dermatological conditions including pyoderma gangrenosum and Behçet's syndrome. We review the current and prospective roles of cytokine blocking agents in the treatment of skin disease.
Original language | English |
---|---|
Pages (from-to) | 585-590 |
Number of pages | 5 |
Journal | Clinical and Experimental Dermatology |
Volume | 27 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2002 |